Glenmede Trust’s Fulgent Genetics FLGT Stock Holding History

Glenmede Trust’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,810	Closed	-$72K	–	1581
2020 Q3	$72K	Buy	1,810 +375	+26%	+$11.7K	﹤0.01%	1253
2020 Q2	$22K	Buy	+1,435	New	+$22K	﹤0.01%	1549

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RJT

Raymond James Trust St. Petersburg, Florida $4.6B AUM 33.54% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Glenmede Trust's FLGT Position: Q4 2020 in Review

Glenmede Trust sold out of Fulgent Genetics (FLGT) in Q4 2020, closing a stake of 1,810 shares — an estimated $72K sold.

Glenmede Trust first reported a position in FLGT in Q2 2020 and held it in 2 quarters. The position peaked at $72K in Q3 2020. 196 funds tracked by Wall St. Rank hold FLGT as of Q4 2020.

Glenmede Trust reported no remaining Fulgent Genetics position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 1,810 Fulgent Genetics shares in Q4 2020, an estimated $72K.
Glenmede Trust first reported a position in Fulgent Genetics in Q2 2020 and held it in 2 quarters.
Glenmede Trust's Fulgent Genetics position peaked at $72K in Q3 2020.
196 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.